Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0666 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.2667 |
| Open | 4.1367 |
| 1-Year Change | 148.33% |
| Day's Range | 4.0767 - 4.1767 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 2, 2025 | 4.2667 | 0.0200 | 0.47% | 4.2467 | 4.3767 | 4.2167 |
| Apr 1, 2025 | 4.3467 | 0.2200 | 5.33% | 4.1267 | 4.4067 | 4.0967 |
| Mar 31, 2025 | 4.2067 | -0.0100 | -0.24% | 4.2167 | 4.3167 | 4.1767 |
| Mar 28, 2025 | 4.3567 | 0.1600 | 3.81% | 4.1967 | 4.4667 | 4.0667 |
| Mar 27, 2025 | 4.0467 | -0.0100 | -0.25% | 4.0567 | 4.2767 | 3.8267 |
| Mar 26, 2025 | 4.3267 | 0.0300 | 0.70% | 4.2967 | 4.3867 | 4.2867 |
| Mar 25, 2025 | 4.3267 | 0.0300 | 0.70% | 4.2967 | 4.4267 | 4.2567 |
| Mar 24, 2025 | 4.3967 | -0.1100 | -2.44% | 4.5067 | 4.5367 | 4.2667 |
| Mar 21, 2025 | 4.5567 | -0.3400 | -6.94% | 4.8967 | 4.9067 | 4.5067 |
| Mar 20, 2025 | 4.8067 | -0.3300 | -6.42% | 5.1367 | 5.2767 | 4.7967 |
| Mar 19, 2025 | 4.9667 | -0.1500 | -2.93% | 5.1167 | 5.4567 | 4.9267 |
| Mar 18, 2025 | 5.0467 | 0.0800 | 1.61% | 4.9667 | 5.2067 | 4.8867 |
| Mar 17, 2025 | 5.1667 | -0.1700 | -3.19% | 5.3367 | 5.5467 | 5.1567 |
| Mar 14, 2025 | 5.4567 | 0.4000 | 7.91% | 5.0567 | 5.4567 | 5.0567 |
| Mar 13, 2025 | 5.2867 | -0.2100 | -3.82% | 5.4967 | 5.5067 | 5.1767 |
| Mar 12, 2025 | 5.5467 | 0.3400 | 6.53% | 5.2067 | 5.5767 | 5.0367 |
| Mar 11, 2025 | 5.0367 | 0.1400 | 2.86% | 4.8967 | 5.1867 | 4.6367 |
| Mar 10, 2025 | 4.9167 | -1.3300 | -21.29% | 6.2467 | 6.2467 | 4.7367 |
| Mar 7, 2025 | 6.2567 | -0.1400 | -2.19% | 6.3967 | 6.4967 | 5.9967 |
| Mar 6, 2025 | 6.5467 | 0.0500 | 0.77% | 6.4967 | 6.6467 | 6.0967 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
| Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com